[go: up one dir, main page]

DK96493D0 - Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden - Google Patents

Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Info

Publication number
DK96493D0
DK96493D0 DK93964A DK96493A DK96493D0 DK 96493 D0 DK96493 D0 DK 96493D0 DK 93964 A DK93964 A DK 93964A DK 96493 A DK96493 A DK 96493A DK 96493 D0 DK96493 D0 DK 96493D0
Authority
DK
Denmark
Prior art keywords
self
proteins
protein
procedure
diseases
Prior art date
Application number
DK93964A
Other languages
English (en)
Inventor
Soeren Mouritsen
Henrik Elsner
Original Assignee
Mouritsen Og Elsner Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mouritsen Og Elsner Aps filed Critical Mouritsen Og Elsner Aps
Priority to DK93964A priority Critical patent/DK96493D0/da
Publication of DK96493D0 publication Critical patent/DK96493D0/da
Priority to JP50727895A priority patent/JP3825041B2/ja
Priority to AT94926106T priority patent/ATE162723T1/de
Priority to DE69408342T priority patent/DE69408342T2/de
Priority to EP94926106A priority patent/EP0752886B1/en
Priority to DK94926106.9T priority patent/DK0752886T3/da
Priority to ES94926106T priority patent/ES2112559T3/es
Priority to PCT/DK1994/000318 priority patent/WO1995005849A1/en
Priority to KR1019960701052A priority patent/KR100308444B1/ko
Priority to AU76080/94A priority patent/AU7608094A/en
Priority to CA002170236A priority patent/CA2170236C/en
Priority to US08/955,373 priority patent/US20020090379A1/en
Priority to GR980400609T priority patent/GR3026419T3/el
Priority to AU70091/98A priority patent/AU707083B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK93964A 1993-08-26 1993-08-26 Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden DK96493D0 (da)

Priority Applications (14)

Application Number Priority Date Filing Date Title
DK93964A DK96493D0 (da) 1993-08-26 1993-08-26 Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
CA002170236A CA2170236C (en) 1993-08-26 1994-08-25 Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
ES94926106T ES2112559T3 (es) 1993-08-26 1994-08-25 Induccion de respuesta de anticuerpos contra proteinas endogenas con ayuda de epitopes de celulas t extrañas.
AT94926106T ATE162723T1 (de) 1993-08-26 1994-08-25 Die induktion der antikörperantwort gegen eigene proteine mit hilfe fremder t-zellepitope
DE69408342T DE69408342T2 (de) 1993-08-26 1994-08-25 Die induktion der antikörperantwort gegen eigene proteine mit hilfe fremder t-zellepitope
EP94926106A EP0752886B1 (en) 1993-08-26 1994-08-25 Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
DK94926106.9T DK0752886T3 (da) 1993-08-26 1994-08-25 Induktion af antistofsvar mod selv-proteiner ved hjælp af fremmede T-celleepitoper
JP50727895A JP3825041B2 (ja) 1993-08-26 1994-08-25 外来ｔ−細胞エピトープを補助として用いた、自己タンパク質に対する抗体応答の誘発
PCT/DK1994/000318 WO1995005849A1 (en) 1993-08-26 1994-08-25 Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
KR1019960701052A KR100308444B1 (ko) 1993-08-26 1994-08-25 이종 t-세포 에피토우프를 사용하여 자가 단백질에 대해항체반응을유도하는방법
AU76080/94A AU7608094A (en) 1993-08-26 1994-08-25 Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
US08/955,373 US20020090379A1 (en) 1993-08-26 1997-10-21 Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
GR980400609T GR3026419T3 (en) 1993-08-26 1998-03-20 Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
AU70091/98A AU707083B2 (en) 1993-08-26 1998-06-11 Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK93964A DK96493D0 (da) 1993-08-26 1993-08-26 Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Publications (1)

Publication Number Publication Date
DK96493D0 true DK96493D0 (da) 1993-08-26

Family

ID=8099485

Family Applications (2)

Application Number Title Priority Date Filing Date
DK93964A DK96493D0 (da) 1993-08-26 1993-08-26 Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DK94926106.9T DK0752886T3 (da) 1993-08-26 1994-08-25 Induktion af antistofsvar mod selv-proteiner ved hjælp af fremmede T-celleepitoper

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94926106.9T DK0752886T3 (da) 1993-08-26 1994-08-25 Induktion af antistofsvar mod selv-proteiner ved hjælp af fremmede T-celleepitoper

Country Status (12)

Country Link
US (1) US20020090379A1 (da)
EP (1) EP0752886B1 (da)
JP (1) JP3825041B2 (da)
KR (1) KR100308444B1 (da)
AT (1) ATE162723T1 (da)
AU (1) AU7608094A (da)
CA (1) CA2170236C (da)
DE (1) DE69408342T2 (da)
DK (2) DK96493D0 (da)
ES (1) ES2112559T3 (da)
GR (1) GR3026419T3 (da)
WO (1) WO1995005849A1 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410022B1 (en) 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
EP0831881B1 (en) 1995-06-06 2003-03-12 Avant Immunotherapeutics, Inc. Cetp for increasing hdl cholesterol level
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
ATE326481T1 (de) 1997-04-15 2006-06-15 Pharmexa As Veränderte tnfalpha-moleküle, dns, welche für derartige veränderte tnfalpha-moleküle kodiert und impfstoffe, die derartige veränderte tnfalpha-moleküle und dns enthalten
US6319503B1 (en) * 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
DK1114166T3 (da) * 1998-09-15 2005-08-01 Pharmexa As Fremgangsmåde til nedregulering af osteoprotegerinligandaktivitet
AU754971B2 (en) * 1998-09-15 2002-11-28 Pharmexa A/S Method for down-regulating osteoprotegerin ligand activity
ID28387A (id) * 1998-10-05 2001-05-17 M & E Biotech As Metoda baru untuk vaksinasi terapeutik
IL141868A0 (en) * 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
DE69929232T2 (de) 1998-10-21 2006-08-31 The United States Government As Represented By The Department Of Health And Human Services Virusähnliche partikel zur induktion von autoantikörpern
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
CA2370391A1 (en) 1999-04-23 2000-11-02 Pharmexa A/S Method for down-regulating il5 activity
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
WO2001005820A2 (en) * 1999-07-20 2001-01-25 Pharmexa A/S Method for down-regulating gdf-8 activity
DE60114157T2 (de) * 2000-02-21 2006-06-29 Pharmexa A/S Verfahren zur herabregulierung von amyloid
CZ20022748A3 (cs) 2000-02-21 2004-03-17 Pharmexa A/S Nová metoda regulace obsahu amyloidu
WO2002020038A2 (en) * 2000-09-06 2002-03-14 Pharmexa A/S Method for down-regulating ige
AU3941002A (en) 2000-10-31 2002-06-03 Zycos Inc Cyp1b1 nucleic acids and methods of use
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
US20030166589A1 (en) * 2001-06-05 2003-09-04 Nathan Karin Method and pharmaceutical composition for the treatment of multiple sclerosis
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
NZ533587A (en) * 2001-11-16 2005-11-25 Pharmexa As Immunogenic mimetics of multimer proteins with promiscuous T cell epitope inserts
WO2003075951A2 (en) * 2002-03-11 2003-09-18 Pharmexa A/S Novel application of vaccination against tnf-alpha
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ES2370688T3 (es) 2002-06-13 2011-12-21 Merck Patent Gmbh Métodos para la identificación de alo-antígenos y su utilización para la terapia contra el cáncer y para el trasplante.
MXPA05006113A (es) * 2002-12-11 2005-09-30 Pharmexa As Epitopos sencillos objetivo.
WO2005025613A1 (en) * 2003-03-12 2005-03-24 Rappaport Family Institute For Research In The Medical Sciences Methods of identifying biomolecular targets for diagnosis and therapy
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
WO2004080273A2 (en) * 2003-03-12 2004-09-23 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating prostate cancer
CA2519313A1 (en) * 2003-03-28 2004-10-07 Katrien Lorre Treatment of type 1 immune response-mediated inflammatory lung disease by modulation of ifn-gamma activity
CN101094864A (zh) 2003-06-25 2007-12-26 法麦克萨有限公司 Her－2变体的纯化
JP4751984B2 (ja) * 2004-09-27 2011-08-17 順 西平 Ｄｎａワクチン
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
NZ563526A (en) * 2005-05-24 2009-02-28 Neovacs A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFalpha and a carrier protein
AU2006312847A1 (en) * 2005-11-09 2007-05-18 Pharmexa A/S Therapeutic vaccines targeting HMGB1
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2007137586A2 (en) * 2006-05-31 2007-12-06 Pharmexa A/S Random insertion of peptides
CA2665068C (en) 2006-10-06 2016-01-05 Bn Immunotherapeutics Inc. Methods for treating cancer with mva
US8053231B2 (en) 2007-04-03 2011-11-08 Jun Nishihira DNA vaccine
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
EP2998322A4 (en) * 2013-05-14 2016-12-14 Shanghai Hycharm Inc EPITOPE BASED VACCINE FOR LOW IMMUNOGENICITY PROTEIN AND METHOD FOR PREPARING AND USING SAME

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983003971A1 (en) * 1982-05-12 1983-11-24 President And Fellows Of Harvard College Hybrid proteins
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US5126399A (en) * 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
EP0269455A3 (en) * 1986-11-28 1989-09-06 Takeda Chemical Industries, Ltd. Highly purified fused protein comprising human ige fc fragment and production thereof
NL8700927A (nl) * 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
ATE130197T1 (de) * 1988-06-14 1995-12-15 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
DE69023900D1 (de) * 1989-02-24 1996-01-11 Univ California Gentechnologisch veränderte immunglobuline.
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
WO1991001330A1 (en) * 1989-07-14 1991-02-07 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
IT1231727B (it) * 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
US5500366A (en) * 1990-09-18 1996-03-19 Biotech Australia Pty. Ltd. Polynucleotide encoding T-cell epitopes of the protein TraT
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
AU634379B2 (en) * 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
WO1993023076A1 (en) * 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
US5716596A (en) * 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses

Also Published As

Publication number Publication date
CA2170236A1 (en) 1995-03-02
JPH09505031A (ja) 1997-05-20
CA2170236C (en) 2007-11-06
DE69408342T2 (de) 1998-05-14
EP0752886A1 (en) 1997-01-15
US20020090379A1 (en) 2002-07-11
JP3825041B2 (ja) 2006-09-20
EP0752886B1 (en) 1998-01-28
KR960704568A (ko) 1996-10-09
ES2112559T3 (es) 1998-04-01
GR3026419T3 (en) 1998-06-30
AU7608094A (en) 1995-03-21
ATE162723T1 (de) 1998-02-15
WO1995005849A1 (en) 1995-03-02
DK0752886T3 (da) 1998-05-04
DE69408342D1 (de) 1998-03-05
KR100308444B1 (ko) 2001-11-30

Similar Documents

Publication Publication Date Title
DK96493D0 (da) Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
RU2363707C2 (ru) Искусственные белки с пониженной иммуногенностью
DK0851927T3 (da) Forbindelser til immunterapi og diagnosticering af tuberkulose
NO991694L (no) Forbindelser og metoder for immunoterapi og diagnose av tuberkulose
ATE229978T1 (de) Helicobacter proteine und impstoffe
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
NO20075902L (no) Forbindelser for immunoterapi og diagnose av turberkolose og metoder for deres anvendelse
AR052377A2 (es) Polipeptidos y polinucleotidos de neisseria meningitidis, un huesped unicelular, un metodo para producir una secuencia de adn, un metodo para producir un polipeptido, un metodo para aislar el antigeno, una composicion farmaceutica, uso de una proteina para producir una vacuna destinada para la preve
DK0469045T3 (da) Syntetiske Pseudomonas aeruginosa pilinpeptider og beslægtede vacciner diagnostica
NZ331989A (en) Arthritogenic peptide, DNAJ, isolated from bacterial peptides and used in vaccine compositions for treating rheumatoid arthritis
AU707083B2 (en) Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
DK0701612T3 (da) Immunogent præparat af OspC-antigenvacciner til forebyggelse og behandling af Lyme sygdom og rekombinantmetode til fremsti
DE3650011D1 (de) EXPRESSION UND DIAGNOSE MIT gag-KODIERTEN PEPTIDEN, DIE MIT ANTIKÖRPERN GEGEN LAV IMMUNOLOGISCH REAKTIV SIND.
DE69520943D1 (de) Malariapeptide
MY105080A (en) Heat-labile toxin b subunit fusion proteins.
SE9001105D0 (sv) New methods foer diagnosis of tuberculosis
DK0687300T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
ATE241385T1 (de) Rekombinante adenovirus-vakzinen
EP0879244A4 (en) RECOMBINANT POLYPEPTIDE VACCINE AGAINST MYCOPLASMS.
Yamabe et al. Antigenic group II chaperonin in Methanobrevibacter oralis may cross‐react with human chaperonin CCT
ES8800052A1 (es) Un procedimiento para preparar una proteina de superficie antigenica de anaplasma marginale
WO2000039301A3 (en) Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
Mountford et al. Fractionation of schistosome antigens by high performance electrophoretic chromatography and their screening for the ability to induce Th1 lymphocyte activity
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
Tollefsen et al. T‐and B‐cell epitopes in the secreted Mycobacterium bovis antigen MPB70 in mice

Legal Events

Date Code Title Description
A0 Application filed
AHS Application shelved for other reasons than non-payment